twoXAR Pharmaceuticals is now ARIA Pharmaceuticals. Read More
Menu
twoXAR Pharmaceuticals is now ARIA Pharmaceuticals. Read More
An aria is an elaborate, sophisticated section in an opera reserved for the top performer. Just as an aria boldly advances the plot, we are dedicated to advancing bold breakthroughs in medicine. At Aria Pharmaceuticals, we believe in the work we do for patients in need. Our name exhibits the artistry and complexity that defines how we approach medicine from idea to FDA approval in a way that is scientifically sound.
Combining his experience as an entrepreneur and technologist with his passion for social responsibility, Andrew co-founded Aria Pharmaceuticals to develop life-saving medicines to help treat patients in need. Prior to co-founding Aria, Andrew held Chief Technology Officer roles at several early-stage companies where he managed teams as large as a hundred technologists distributed around the world. Andrew developed the company’s proprietary platform and as Chief Executive Officer is focused on overall company strategy, product development and fundraising. Andrew studied biomedical informatics in Stanford University’s SCPD graduate program and holds Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology.
One of Aria Pharmaceuticals’ first employees, Aaron has helped build Aria’s drug discovery platform and leads the Discovery Science team’s efforts to discover potential treatments across a wide range of diseases. Aaron earned his PhD in Genetics from Stanford University. Prior to his time at Stanford, Aaron was a Fulbright Scholar and received his Bachelor of Science in Biology from the University of Richmond.
Prior to joining Aria Pharmaceuticals, Brian held Vice President–level positions at leading technology companies including Hewlett-Packard and Sun Microsystems in the Finance, Human Resources, and Corporate Development functions. Prior to his work in industry, Brian advised clients as an investment banker. Throughout his deal-making career, Brian has closed more than 50 deals constituting more than $15 billion in transaction value. Brian holds an MBA from Kellogg School of Management at Northwestern University where he was awarded the F.C. Austin Scholarship and a BA from UC Davis where he majored in English and Economics.
